TrialThe Lancet. Respiratory medicine2014

Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.

Mario Castro et al.PubMed ↗Publisher ↗

No numbers read from the abstract.